A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4Bradley Vince, Xiao-Jian Zhou, Eric Lawitz et al.|Journal of Hepatology|2014Cited by 23